Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Stopped early · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help docetaxel work better and kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with hydroxychloroquine works in treating patients with metastatic prostate cancer.
Key facts
- Study ID
- NCT00786682
- Run by
- University of Medicine and Dentistry of New Jersey
- People needed
- 11
- Starts
- 2008-12-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2023-08-14
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States
- Mountainside Hospital — Montclair, New Jersey, United States
- Carol G. Simon Cancer Center at Morristown Memorial Hospital — Morristown, New Jersey, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
- St. Peters University Hospital — New Brunswick, New Jersey, United States
- Overlook Hospital — Summit, New Jersey, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.